LFM-A13 – 5 mg

Brand:
Cayman
CAS:
244240-24-2
Storage:
-20
UN-No:
Non-Hazardous - /

Bruton’s tyrosine kinase (BTK) is a member of the BTK/Tec family of protein tyrosine kinases involved in signal transduction pathways regulating growth and differentiation of B cells. BTK acts as an inhibitor of Fas/APO-1-mediated apoptosis in B cells by preventing FAS-FADD interaction.{15125} LFM-A13 is an anti-leukemia agent with apoptosis-promoting and chemosensitizing properties.{15126,15125} It acts as an inhibitor of Bruton’s tyrosine kinase (BTK) and Polo-like kinase (Plk) with IC50 values of 2.5 µM (mouse recombinant) and 10 µM (Xenopus), respectively.{15126,15124} LFM-A13 exhibits minor inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and Cdk1, 2 and 3, as well as several other related kinases.{15126,15124} LFM-A13 also exhibits anti-proliferative activity against HER2/Neu-overexpressing breast cancer cells.{15124}  

 

Available on backorder

SKU: 10010265 - 5 mg Category:

Description

An anti-leukemia agent with apoptosis-promoting and chemosensitizing properties; inhibits Bruton’s tyrosine kinase (BTK) and Polo-like kinase (Plk) with values of 2.5 µM (mouse recombinant) and 10 µM (Xenopus), respectively


Formal name: 2Z-cyano-N-(2,5-dibromophenyl)3-hydroxy-2-butenamide

Synonyms: 

Molecular weight: 360

CAS: 244240-24-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Plks||Product Type|Biochemicals|Kinase Inhibitors|Tec Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|PLK Signaling||Research Area|Cancer|Cell Signaling|Tec Family Signaling